Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
|
Ultragenyx Pharmaceutical Inc. (RARE)
|
Add to portfolio |
|
|
|
| Price: |
$84.40
| | Metrics |
| OS: |
70.0
|
M
| |
|
|
| Market cap: |
$5.91
|
B
| |
|
|
|
Net cash:
|
$706
|
M
| |
$10.08
|
per share
|
|
EV:
|
$5.21
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 351.4 | 271.0 | 103.7 | 51.5 | 2.6 | 0.1 | 0.0 | 0.0 |
| Revenue growth | 29.7% | 161.3% | 101.4% | 1871.5% | 1863.9% | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 1.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 351.4 | 271.0 | 103.7 | 50.3 | 2.6 | 0.1 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 97.8% | 100.0% | 100.0% | | |
| Selling, general and administrative | 0.0 | 0.0 | 0.0 | 127.7 | 99.9 | 64.9 | 33.0 | |
| Research and development | | | | 294.0 | 231.6 | 183.2 | 114.7 | 46.0 |
| General and administrative | 0.0 | 0.0 | 0.0 | | | | | 10.8 |
| EBIT | -452.7 | -184.4 | -396.8 | -201.1 | -328.9 | -248.0 | -147.7 | -56.8 |
| EBIT margin | -128.8% | -68.0% | -382.6% | -390.4% | -12593.5% | -186471.4% | | |
| Pre-tax income | -453.0 | -185.4 | -399.4 | -197.1 | -318.3 | -245.8 | -145.6 | -59.8 |
| Income taxes | 1.0 | 1.2 | 3.3 | 0.5 | -16.2 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | 5.1% | | 0.0% | 0.0% |
| Net income | -454.0 | -186.6 | -402.7 | -197.6 | -302.1 | -245.9 | -145.6 | -64.6 |
| Net margin | -129.2% | -68.8% | -388.3% | -383.7% | -11567.3% | -184867.7% | | |
| |
| Diluted EPS | ($6.70) | ($3.07) | ($7.12) | ($3.97) | ($7.12) | ($6.21) | ($3.96) | ($2.25) |
| Shares outstanding (diluted) | 67.8 | 60.8 | 56.6 | 49.8 | 42.5 | 39.6 | 36.8 | 28.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|